A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.

@article{Murata2014ACO,
  title={A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.},
  author={Masayuki Murata and Norihiro Furusyo and Eiichi Ogawa and Fujiko Mitsumoto and Satoshi Hiramine and Hiroaki Ikezaki and Koji Takayama and Motohiro Shimizu and Kazuhiro Toyoda and Mosaburo Kainuma and Jun Hayashi},
  journal={Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy},
  year={2014},
  volume={20 5},
  pages={320-4}
}
In Japan, the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection of some patients with hemophilia was caused by the transfusion of imported blood products, such as unheated coagulation factor. With the development of antiretroviral therapy (ART) for HIV, chronic HCV infection has become a major cause of liver disease and mortality for hemophiliac patients coinfected with HCV/HIV. Data is limited regarding the efficacy and safety of antiviral therapy with the HCV protease… CONTINUE READING